6/28/23, 11:40 PM Imatinib-IPF Pathway Feedback Search Clinical Topics Home Studies Imatinib-IPF Imatinib-IPF Disease Idiopathic pulmonary fibrosis Trial question What is the role of imatinib in patients with idiopathic pulmonary fibrosis? Study design Multi-center Double blinded RCT Population Characteristics of study participants 29.0% female N = 119 71.0% male 119 patients (35 female, 84 male) Inclusion criteria: patients with idiopathic pulmonary fibrosis Key exclusion criteria: an alternate explanation for the presence of fibrotic lung disease or known connective tissue disease, women of childbearing age or breast-feeding, obstructive lung disease, active infection, unstable or deteriorating cardiac or neurologic disease, Interventions N=59 imatinib (Gleevec 600 mg, six tablets PO once daily for a period of 96 weeks) N=60 placebo (matching placebo for 96 weeks) Primary outcome No significant difference in change in diffusing capacity of CO at 96 weeks (-1.1 vs. -1.6; ARD 0.5, 95% CI -0.7 to 1.7) Secondary outcomes https://web.pathway.md/studies/recPTzRPPUps2JKZd 1/2 6/28/23, 11:40 PM Imatinib-IPF Pathway Significant increase in change in resting Pa(O2) at 96 weeks (0.3 vs. -5.6; ARD 5.9, 95% CI 5.9 to 5.9) Safety outcomes No significant differences in deaths (p=0.64), discontinuation of study drug (32% vs. 27%, p=0.51), and serious adverse events (18 vs. 19). Conclusion In patients with idiopathic pulmonary fibrosis, imatinib was not superior to placebo with respect to change in diffusing capacity of CO at 96 weeks. Reference Daniels CE, Lasky JA, Limper AH et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. Open reference URL https://web.pathway.md/studies/recPTzRPPUps2JKZd 2/2